Tech Company Financing Transactions
AmpliMed Funding Round
AmpliMed secured a $8.5 million Series B funding round on 11/28/2006. Backers included Biotech Insight Ventures, DPEC Partners and Solstice Capital.
Transaction Overview
Company Name
Announced On
11/28/2006
Transaction Type
Venture Equity
Amount
$8,500,000
Round
Series B
Investors
Proceeds Purpose
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
1730 E River Rd. 100-A
Tucson, AZ 85718
USA
Tucson, AZ 85718
USA
Phone
Website
Email Address
Not Recorded
Overview
AmpliMed Corporation, a clinical-stage pharmaceutical company founded by world-renowned oncologists, has a lead compound, Amplimexon, in Phase II clinical trials, with early evidence of efficacy and low levels of toxicity.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Robert Dorr
Browse more venture capital transactions:
Prev: 11/28/2006: OZ Communications venture capital transaction
Next: 11/28/2006: Tangoe venture capital transaction
Share this article
About Our VC Transactions Data
We do our best to report on every notable VC transaction. VC transactions reported here are sourced from publicly available VC deal announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs